{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:27:22Z","timestamp":1769527642610,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ygyno.2017.05.033","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T04:31:38Z","timestamp":1500352298000},"page":"554-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"146","author":[{"given":"John K.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Bonebrake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weldon","family":"Chafe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.05.033_bb0005","series-title":"Clinical Gynecologic Oncology","author":"Di Saia","year":"2012"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0015","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0020","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/bjc.1997.571","article-title":"Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia","volume":"76","author":"Dobbs","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0025","first-page":"1294","article-title":"Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice","volume":"57","author":"Smith-McCune","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0030","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0035","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0040","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1053\/jhep.2002.32541","article-title":"Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma","volume":"35","author":"Yoshiji","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0045","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1021\/jm060347y","article-title":"Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2","volume":"49","author":"Borzilleri","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0050","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1158\/1078-0432.CCR-08-0509","article-title":"Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma","volume":"14","author":"Huynh","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0055","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-06-4555","article-title":"Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2\/FGFR-1 antagonist","volume":"67","author":"Ayers","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0060","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2012.46.0543","volume":"31","author":"Siu","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0065","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2014.07.083","article-title":"A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"135","author":"Powell","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050019","article-title":"Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting","volume":"5","author":"Pietras","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2012.09.008","article-title":"Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a Gynecologic Oncology Group study","volume":"127","author":"Alberts","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0272","article-title":"A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium","volume":"63","author":"Sutton","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2005.09.009","article-title":"Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"100","author":"Brewer","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2008.03.009","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.1999.17.3.756","article-title":"Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix","volume":"17","author":"Pignata","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/gyno.2000.5807","article-title":"Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"77","author":"Bookman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2005.11.048","article-title":"Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"102","author":"Rose","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2011.05.040","article-title":"Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"122","author":"Santin","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0140","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Symonds","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0145","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0150","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/IGC.0b013e3181a83467","article-title":"A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"19","author":"Schilder","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2013.05.008","article-title":"Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)","volume":"130","author":"Tinker","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0160","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0165","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2012.01.036","article-title":"Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study","volume":"48","author":"Feldt","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","article-title":"Hypertension and proteinuria: a class-effect of antiangiogenic therapies","volume":"20","author":"Launay-Vacher","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/bjc.2011.182","article-title":"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy","volume":"105","author":"Garrett","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0180","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2017.05.033_bb0190","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0195","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.2015.313","article-title":"A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results","volume":"113","author":"Eisen","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"35","key":"10.1016\/j.ygyno.2017.05.033_bb0200","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2014.10.001","article-title":"A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"1","author":"Dizon","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.033_bb0205","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-13-3006","article-title":"Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer","volume":"20","author":"Escudier","year":"2014","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T04:59:34Z","timestamp":1535605174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0090825817308892"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.033","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}